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terminase subunits
Jian Ben Wang1, Yali Zhu2, Michael A McVoy1* and Deborah S Parris2

Abstract
Background: During herpesvirus replication, terminase packages viral DNA into capsids. The subunits of herpes
simplex virus terminase, UL15, UL28, and UL33, assemble in the cytoplasm prior to nuclear import of the complex.
Methods: To detect similar interactions between human cytomegalovirus terminase subunits, the orthologous
proteins UL89, UL56, and UL51 were expressed in HEK-293 T cells (via transfection) or insect cells (via baculovirus
infection) and subcellular localizations were detected by cellular fractionation and confocal microscopy.
Results: In both cell types, UL56 and UL89 expressed alone were exclusively cytoplasmic, whereas UL51 was ~50%
nuclear. Both UL89 and UL56 became ~50% nuclear when expressed together, as did UL56 when expressed with
UL51. Nuclear localization of each protein was greatest when all three proteins were co-expressed.
Conclusions: These results support inclusion of UL51 as an HCMV terminase subunit and suggest that nuclear
import of human cytomegalovirus terminase may involve nuclear import signals that form cooperatively upon
subunit associations.
Keywords: Herpesvirus, Cytomegalovirus, Terminase, DNA packaging, Genome maturation

Background
Herpesviruses have large (130 - 235 kb) linear doublestranded DNA genomes that replicate via concatemeric
intermediates consisting of head-to-tail linked genomes.
An enzyme complex called terminase functions to package the DNA into preformed capsids and cleave the concatemers at precise locations to release unit length
genomes within the capsids [1]. The herpes simplex
virus type 1 (HSV-1) proteins UL15, UL28, and UL33
are believed to comprise the HSV-1 terminase. Studies
have also detected interactions between UL56 and UL89
[2,3], the human cytomegalovirus (HCMV) orthologs of
HSV-1 UL28 and UL15, respectively. The possible inclusion of UL51 as part of the HCMV terminase has been
inferred as it is an ortholog of HSV-1 UL33. Here, we
show evidence that co-expression of UL56 with UL89 or
UL56 with UL51 is necessary for nuclear import of
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UL56 or UL89 in the absence of any other viral proteins.
These results suggest that UL51 is a component of the
HCMV terminase and that specific interactions among
terminase subunits in the cytoplasm are prerequisites for
its nuclear importation.

Results
Each subunit was expressed using recombinant baculoviruses. PCR overlap extension was used to modify the
5’ end of the UL51 ORF to encode an N-terminal FLAG
epitope. Sf9 insect cells were infected with 3 pfu/cell of
each baculovirus individually, or co-infected with pairwise combinations or with all three viruses. After 48 h,
soluble cytoplasmic and nuclear fractions were prepared
and analyzed by immunoblotting. UL56 and UL89 were
detected using polyclonal rabbit antisera and UL51 was
detected using a FLAG epitope-specific mouse monoclonal antibody. To ensure efficient separation of nuclear
from cytoplasmic material, blots were also probed with
antibodies to the exclusively cytoplasmic protein (tubulin) or to the exclusively nuclear protein (histone H4).
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When expressed alone, UL51 (17 kDa) was equally distributed between the cytoplasm and the nucleus,
whereas UL56 (96 kDa) and UL89 (77 kDa) were found
exclusively in the cytoplasm (Figure 1). Distribution of
UL51 was not significantly affected by co-expression
with other proteins; however, dual expression of UL56
with either UL51 or UL89 resulted in redistribution of
about half of the UL56 to the nucleus. Similarly, dual expression of UL89 with UL56 resulted in redistribution of
about half of the UL89 to the nucleus. When all three
proteins were expressed, each protein appeared to be
equally distributed between cytoplasmic and nuclear
fractions (Figure 1).
To determine if similar localization patterns occur in
human cells, mammalian plasmid expression vectors
were engineered to express UL51, UL56, or UL89 fused
to N-terminal FLAG, V5, or MYC epitope tags, respectively. HEK-293 T cells were transfected with plasmid
vectors individually or in combinations. After 48 h the
cells were permeabilized and the subcellular localization
of each protein was determined by confocal microscopy
using fluorescent-tagged epitope-specific monoclonal
antibodies (Figure 2). UL51 was often found in both the
cytoplasm and the nucleus, with 41% of cells exhibiting
nuclear staining. This proportion was not significantly
altered by the presence of the other proteins. UL56 was
exclusively cytoplasmic when expressed alone, but the
percentage of cells with nuclear staining increased to
62% in the presence of UL51, 37% in the presence of
UL89, and 74% when all three proteins were present.
UL89 was also exclusively cytoplasmic when expressed
alone, but unlike UL56, its localization was not affected

by co-expression of UL51. However, the percentage of
cells with UL89 nuclear staining increased to 26% in the
presence of UL56 and to 80% when all three proteins
were present (Figure 2).

Discussion
The results from these experiments suggest that when
expressed individually, both UL56 and UL89 are strictly
cytoplasmic but co-expression promotes nuclear
localization of both proteins. This could be a result of
each protein harboring a partial nuclear localization signal (NLS) that is functional only when the two proteins
interact, or due to protein interactions that alter conformation of at least one component to expose an otherwise hidden NLS. In either case, the data suggest that
UL56 and UL89 interact. That UL56 can localize to the
nucleus when co-expressed with UL51 also suggests that
UL56 and UL51 interact in the cytoplasm to form a
complex that can be transported to the nucleus. Again,
interaction with UL51 could promote conformational
changes that expose an NLS within UL56, or translocation of the complex could be mediated by an NLS in
UL51. It is uncertain whether UL51 contains an NLS as
its small size (~17 kDa) should allow nuclear entry independent of the nuclear pore complex.
While these results indicate that the two-subunit
UL51/56 or UL56/89 complexes can form in the cytoplasm and subsequently localize to the nucleus, it cannot
be ascertained from our studies whether all three proteins interact to form three-subunit UL51/56/89 complexes. Moreover, while we observed no evidence for
UL51-UL89 interaction, it is possible that interactions
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Figure 1 Subcellular localization of terminase subunits expressed using recombinant baculoviruses. Sf9 insect cells were infected at MOI = 3
with recombinant baculoviruses expressing UL56, UL89, or FLAG-UL51, as indicated. Soluble cytoplasmic (C) and nuclear (N) extracts were prepared 48 h
post infection and analyzed by immunoblot using antibodies specific to each protein as indicated. Cytoplasmic and nuclear fractions were separated on
different gels; for ease of comparison lanes from each are displayed side-by-side. In some blots anti-UL89 antibody cross-reacted with a cellular protein
that migrated more slowly than UL89 (e.g., in the UL51/UL56 cytoplasmic extract).
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Figure 2 Subcellular localization of terminase subunits expressed by plasmid transfection. HEK-293 T cells were transfected with
expression vectors encoding each terminase subunit fused to N-terminal FLAG (UL51), V5 (UL56), or MYC (UL89) epitope tags. 72 h post
transfection the cells were fixed and stained with monoclonal antibodies specific to each epitope tag. The anti-V5 antibody was directly
conjugated to FITC, whereas unconjugated primary antibodies for FLAG and MYC were detected using a FITC-conjugated anti-mouse IgG
secondary antibody. Cells were counter stained with DAPI to detect nuclei. Paired images are representative micrographs taken at 0.7x (top) or 2x
(bottom) zoom. In each column, cells were stained to detect the protein indicated above the column, while the expression vectors that were
transfected are indicated to the left of each image pair. The percentages of cells with nuclear staining (in white) were determined by counting
>50 fluorescent cells per group.
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were missed due to epitope tags on plasmid-expressed
proteins or baculovirus-expressed UL51. A paper published following submission of this report confirms an
essential role for UL51 in DNA packaging and demonstrates that each protein co-precipitates the other two
[4]. Even so, co-precipitation or nuclear colocalization
could be due to the ability of UL56 to interact independently with UL51 and UL89. However, if this were the
case, the presence of UL51 should not increase the nuclear localization of UL89 in cells expressing all three
proteins, but rather, UL51 might impair the nuclear
localization of UL89 by competing for UL56 binding. In
fact, in our studies nuclear localization of UL89, UL56,
and UL51 all increased significantly when all three proteins were co-expressed in transfected 293 T cells
(Figure 2).
In agreement with our results, Borst et al. demonstrated that nuclear localization of UL89 and UL56 was
severely diminished, though not apparently eliminated,
in HCMV-infected cells when UL51 was knocked down
[4]. Surprisingly, these authors were unable to detect
cytoplasmic localization of UL89 and/or UL56 by immunofluorescence when UL51 protein was severely
diminished. However, since knock down of UL51 did
not impact immunoblot levels of UL89 or UL56, it is
likely that immunofluorescence was not sensitive enough
to detect these proteins when they were dispersed in the
cytoplasm. Taken together, these data suggest that threesubunit complexes likely form in the cytoplasm and are
more efficiently imported to the nucleus when all are
present, because of cooperativity between the NLS
formed between UL56 and UL89 and perhaps between
UL56 and UL51, or because of conformational changes
induced by interactions that expose a nuclear
localization signal. The proposed interactions that effect
transport of the terminase holoenzyme and its putative
subunits are summarized in Figure 3.
Interactions between terminase subunits were first
suggested by observations that the UL28 proteins of

pseudorabies virus or HSV-1 are translocated to the nucleus when co-expressed with the UL15 protein of HSV1 and that they co-purify as a complex in infected cells
[5-7]. Subsequent studies implicated UL33 as an additional subunit of terminase complexes [8] and demonstrated direct UL28-UL15 and UL28-UL33 interactions
and a UL28-dependent indirect interaction between
UL15 and UL33 [9-13]. Our studies indicate functional
interactions between HCMV orthologs UL56 and UL89
and between UL56 and UL51. Moreover, data reported
by Borst et al. after our findings were submitted for publication indicate that UL51, UL89, and UL56 coprecipitate from HCMV-infected cell lysates, further
suggesting that all three proteins exist in the same
complex [4]. Interactions between terminase subunit
orthologs of varicella zoster virus, Kaposi’s sarcomaassociated herpesvirus, and murine cytomegalovirus
(MCMV) have also been reported [14-17].
The studies presented here are the first to characterize
the intracellular trafficking of UL89 outside the context
of infected cells and they directly implicate UL51 as a
subunit of the HCMV terminase by virtue of its interaction with UL56. Borst et al. [4] also implicate UL51 as
an essential member of the HCMV terminase complex
since, despite normal levels of DNA replication, DNA
cleavage and genome packaging into virions fail to occur
when UL51 is knocked down in HCMV-infected cells.
Because we were able to track localization of each subunit when expressed alone or with each of the other proteins, we were able to demonstrate an interdependence
between UL56 and UL89 for nuclear transport even in
the absence of UL51. This is consistent with prior
reports of UL56-UL89 interaction and their colocalization to nuclear viral replication centers in
HCMV-infected cells [2,3,18,19]. However, contrary to
our findings, Giesen et al. detected UL56 in the nuclei of
transfected COS7 cells in the absence of other HCMV
proteins and mapped a putative NLS [18]. This may suggest that UL56 localization is cell type-dependent as
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Figure 3 Summary of terminase subunit interactions for HSV-1 and HCMV. HCMV terminase subunit complexes that result in nuclear
transport are illustrated. NLS, nuclear localization signal; Ø, no interaction, no nuclear translocation.
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UL56 failed to localize to the nuclei of insect cells or
human HEK-293 T cells in our studies. It should
be pointed out that neither our studies nor those of
Borst et al. [4] have demonstrated direct protein-protein
interactions between subunits despite the fact that they
co-localize or co-precipitate. However, even if such
interactions are indirect, our studies indicate that they
do not involve an additional viral protein, although a cellular protein present in both insect and human cells
could be required. Work is in progress to rule out such
a possibility.
Thus, despite strong sequence conservation between
orthologous terminase subunits, it appears that HCMV
and HSV-1 have evolved subtle differences in nuclear
import of terminase complexes. For HSV-1 import of
terminase to the nucleus relies on an overt NLS in
UL15, whereas in HCMV the orthologous subunit
(UL89) clearly lacks nuclear transport capacity. Terminase instead appears to rely on nuclear import signals
formed cooperatively between the three subunits. Nevertheless a common theme is emerging that terminase
must assemble in the cytoplasm before it can move to
the nucleus. Presumably this restriction serves an important purpose, perhaps preventing uncomplexed or incorrectly complexed subunits from exerting detrimental
effects on the cleavage/packaging process.
The specific function of HCMV UL51 or its orthologs,
remains unknown. Given that HSV-1 UL33 enhances
the UL15-UL28 interaction [9] and that HCMV UL51
(or all three of the putative terminase subunits) is
required for efficient nuclear localization of these subunits, a role for UL33 or UL51 orthologs in promoting or
stabilizing optimal terminase conformation can be envisioned. Moreover, the report that the varicella zoster
virus UL33 ortholog exhibits a plethora of interacting
partners [16] has fueled speculation that UL33-family
proteins may serve a more general role in stabilizing
protein complexes [14]. Recent interactome analyses of
the UL33 orthologs of MCMV and varicella zoster virus
revealed interactions with tegument proteins as well proteins involved in transport of newly formed viral capsids
across the nuclear membrane [17,20]. Such findings,
combined with evidence that UL51 and its MCMV
ortholog are present in virions [21,22], suggest that
UL33-family proteins may mediate or stabilize proteinprotein interactions that link DNA encapsidation with
post-packaging processes of tegumentation and nuclear
egress [17,20].

Conclusions
The results support inclusion of UL51 as an HCMV terminase subunit and suggest that nuclear import of
HCMV terminase may involve nuclear import signals
that form cooperatively upon subunit associations. In

Page 5 of 8

recent years DNA maturation has emerged as a target
for development of novel antivirals. Several “maturational” inhibitors have been identified [23-28]. Letermovir (AIC246), a recent candidate with potent activity
against HCMV, has entered phase IIb clinical trials
[29-32]. Dissection of the mechanisms of action of these
inhibitors and identification of additional candidates
would be considerably advanced by a better understanding of the structure and functions of terminase subunits
and the holoenzyme.

Methods
Plasmid and baculovirus expression vector construction

Oligonucleotide primers used for vector construction
are listed in Table 1. The UL51 coding sequence was
PCR amplified from HCMV strain AD169 DNA with
primer pair MOL269/MOL270 and ligated into pCR-XLTOPO (Invitrogen) to make plasmid pMA319. An XbaI/
HindIII fragment of pMA319 containing UL51 sequences
was then ligated into XbaI/HindIII-restricted pFastbac1
(Invitrogen) to make plasmid pMA320. FLAG-UL51 expression plasmid pMA323 was constructed by PCR amplification of pMA320 with primer pair UL51-FLAG-H3F/
UL51-FLAG-ER1R (which introduce flanking HindIII
and EcoRI sites) and ligation of the HindIII/EcoRI-digested
PCR product into HindIII/EcoRI-digested pcDNA2FLAGAB, a modification of pcDNA3 to express Nterminal FLAG fusions [33]. Baculovirus shuttle plasmid pMA326 was constructed by PCR amplification of
pMA323 with primer pair UL51-FLAG-BamHI/UL51FLAG-ER1R (which introduce flanking BamHI and
EcoRI sites) and ligation of the BamHI/EcoRI-digested
PCR product into BamHI/EcoRI-digested pFastbac1.
The UL56 coding sequence was assembled by PCR
amplification of HCMV strain AD169 DNA using primer
pairs MOL60/MOL64 and MOL59/MOL65 and cloning
of the products into pGEM-T vector (Promega) to generate plasmids pMA48 and pMA49, respectively. An
NcoI/XhoI fragment of pMA48 was then ligated into
NcoI/XhoI-restricted pFastbac-HTa (Invitrogen) to make
plasmid pMA50 and an NcoI fragment from pMA48
was inserted into NcoI-digested pMA50 make plasmid
pMA51. An XhoI/SalI fragment from pMA49 was then
inserted into XhoI-digested pMA51 to make baculovirus
shuttle plasmid pMA52. V5-UL56 expression plasmid
pMA334 was constructed by PCR amplification of
pMA52 with primer pair UL56-V5-F/UL56-V5-R, cloning the product into pCR8/GW/TOPO (Invitrogen) to
make plasmid pMA325, and LR clonase transfer of the
insert to pcDNA3.1/nV5-DEST (Invitrogen).
The cDNA of UL89 was prepared by RT-PCR of RNA
isolated from MRC-5 cells 72 hours post infection with
HCMV strain AD169 using ULTRASPEC RNA (BiotecX).
The RT-PCR reaction used SuperScriptTM II RNase H
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Table 1 Oligonucleotides used for plasmid construction
Plasmid

contains

Oligonucleotide

Sequence (5'-3')*

pMA319

UL51

MOL269

ATGTCCTGGGCTAAGCAGCG

MOL270

TTATTTACCCGGCGCCGACT

MOL60

CCATGGAGATGAATTTGTTAC

MOL64

CTCCTCGAGAATATGCTTGAT

MOL59

ACAGGTTAACGCAGACTACCA

MOL65

ATATTCTCGAGGAGATTCGAC

pMA48

UL56 (5’)

pMA49

UL56 (3’)

pUL89

UL89 cDNA

pMA323
pMA326
pMA325
pMA324

FLAG-UL51
FLAG-UL51
UL56
MYC-UL89

MOL53

CTGCTGCGTGCCTAGCTGAC

MOL54

CATCATGTTGCGCGGAGACT

UL51-FLAG-H3F

GACCTAAGCTTTCCTGGGCTAAGCAGCGGGTG

UL51-FLAG-ER1R

TACGATGAATTCTTATTTACCCGGCGCCGACTC

UL51-FLAG-BamHI

CGGGATCCATGGACTACAAGGACGACGA

UL51-FLAG-ER1R

TACGATGAATTCTTATTTACCCGGCGCCGACTC

UL56-V5-F

GAGATGAATTTGTTACAGAAACTA

UL56-V5-R

TTAACGCAGACTACCAGGCAC

linkA

GATCCACCATGGAACAAAAACTCATCTCAGAAGAGGATCTGG

linkB

AATTCCAGATCCTCTTCTGAGATGAGTTTTTGTTCCATGGTG

UL89-NMyc-ER1F

CATGATGAATTCTTGCGCGGAGACTCGGCC

UL89-NMyc-XB1R

TACATGTCTAGACTAGCTGACCCTGAAACG

*restriction sites used for cloning are underlined.

reverse transcriptase (Gibco BRL) and primer pair MOL53/
MOL54. The product was cloned into pGEM-T vector to
make plasmid pUL89. An SpeI/SphI fragment of pUL89
containing UL89 cDNA sequences was then ligated into
SpeI/SphI-restricted pFastbac1 to make baculovirus shuttle
plasmid pMA38. MYC-UL89 expression plasmid pMA324
was constructed by ligation of annealed oligonucleotides
linkA and linkB into EcoRI/BamHI-restricted pcDNA4/TO
(Invitrogen) to make pcDNA4/TO-c-myc followed by
insertion of an EcoRI fragment containing HSV-1 US11 to
make pCDNA4/TO-myc-US11. US11 sequences were then
removed by EcoRI/XbaI digestion and replaced with UL89
coding sequences by ligation to an EcoRI/XbaI-digested
PCR product amplified from pMA38 using primer pair
UL89-NMyc-ER1F/UL89-NMyc-XB1R (which introduce
flanking EcoRI and XbaI sites). All expression vectors were
verified by sequencing.
Baculovirus shuttle plasmids pMA326, pMA52, and
pMA38 were used as directed in the BAC-to-BAC
baculovirus system (Invitrogen, Grand Island, NY) to
construct recombinant baculoviruses expressing FLAGUL51, 6xhis-UL56, and UL89, respectively.

supernatants were adjusted to 1 μg/ml aprotinin, leupeptin, and pepstain. Nuclei were suspended in 2 packed
volumes of 20 mM Tris-HCl, pH8.2, 2 M NaCl, 2 mM
EDTA, 2 mM 2-mercaptoethanol, 0.5 mM phenylmethylsulfonylfluoride and rocked gently at 4°C for
30 min. Nuclear fractions were clarified by centrifugation at 70,000 × g for 30 min. at 4°C. Soluble nuclear and
cytoplasmic extracts were separated by SDS-PAGE and
electrophoretically transferred to nitrocellulose membranes. Membranes were probed with rabbit antisera to
UL56 (WAR8, raised against an E. coli-expressed GST
fusion to UL56 residues 383-850, a gift from Tom
Jones), UL89 (WAR21, raised against an E. coliexpressed GST fusion to UL89 residues 1-296, a gift
from Tom Jones), or histone H4 (ab 10158, Abcam), or
with mouse monoclonal antibodies to FLAG (F3165,
Sigma) or tubulin (ab 6161, Abcam). Blots were developed using goat anti-mouse (Jackson Immunotherapeutics) or anti-rabbit (Thermo) IgG conjugated to horse
radish peroxidase and the SuperSignal West Pico (GE
Healthcare) luminescent substrate, followed by exposure
to X-ray film.

Immunoblotting

Transient expression and confocal microscopy

Sf9 insect cells were infected with 3 pfu/cell of each
baculovirus individually, or co-infected with pairwise
combinations or with all three viruses. After 48 h,
cytoplasm was separated from nuclei by dounce
homogenization in hypotonic buffer followed by lowspeed centrifugation as described [34]. Cytoplasmic

HEK-293 T cells were transfected with plasmid vectors
individually or in combinations using Effectene (Qiagen).
After 48 h the cells were permeabilized with cold methanol,
blocked with phosphate buffered saline containing 1% BSA,
and stained either with fluorescein isothiocyanate (FITC)conjugated anti-V5 monoclonal antibody (Invitrogen),
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or unconjugated anti-MYC (Sigma) or M2 anti-FLAG
monoclonal antibody (Sigma) followed by a FITCconjugated anti-mouse IgG1 (Serotec) secondary antibody.
Cells were counterstained with 1 μg/ml of 4', 6-diamidino2phenylindole (DAPI). Images were collected using an
LSM 510 Meta confocal laser scanning microscope with
63X oil immersion objective (numerical aperture 1.4), pinhole 0.7 μm, and excitation of 488 nm (FITC) or 405 nm
(DAPI).
Abbreviations
HSV-1: Herpes simplex virus type 1; HCMV: Human cytomegalovirus;
NLS: Nuclear localization signal; MCMV: Murine cytomegalovirus;
FITC: Fluorescein isothiocyanate; DAPI: 4', 6-diamidino-2phenylindole (DAPI).
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